FDA Class I Device Recalls: 3,510 Events, Firms, and Trends Since 2006

Executive Summary

FDA Class I recalls represent the most serious category of medical device recall — situations where there is a reasonable probability that use of the device will cause serious adverse health consequences or death. Our analysis of the complete FDA enforcement report database reveals 3,510 Class I recall events from 2006 through June 2026, with the most recent period showing an alarming escalation.

Speaking at the 2026 MedCon conference, FDA's Anne Reid, director of the Office of Medical Device and Radiological Health Inspectorate (OMDRHI), noted that Class I recalls increased by 232% between 2020 and 2025. "[T]hat is a concerning number for us," she said.

Our independent count moves in the same direction. Tallying each Class I entry in the public enforcement-report database, events rose from 159 in 2020 to 377 in 2025 — a 137% increase over the same period FDA cites at 232%. The two figures differ in magnitude because this dataset counts each enforcement-report entry (so a single multi-model action such as Teleflex's 2023 recall, which affected 123 device models, contributes 123 entries) while FDA's percentage reflects the agency's own tally, and enforcement records are continually added and reclassified. Setting aside the 2014 anomaly (554 events, dominated by Customed, Inc.'s 412 single-event recalls), the 2023–2025 period represents the highest sustained level of Class I activity in the enforcement database's history.

The firms most frequently associated with Class I recalls in recent years are Medtronic (330 events across two divisions), Boston Scientific (131), Teleflex (129), and Philips Respironics (79). Catheter-related devices, ventilation and breathing circuit equipment, and infusion pumps are the device categories most likely to trigger a Class I classification.

This article provides a quantitative breakdown of Class I recalls by year, responsible firm, device category, root-cause patterns, and geographic distribution — giving quality and regulatory professionals a data-driven benchmark for their own recall risk assessment.

Data Source and Methodology

All statistics in this article are derived from our direct analysis of the FDA enforcement report database (public dataset, extracted June 2026), which contains 39,096 classified recall events with recall number, product description, reason for recall, recalling firm, classification (Class I / II / III), status, recall initiation date, product code, state, and country.

Class I recalls are the subset where classification = 'Class I', yielding 3,510 events. Year assignment is based on recall_initiation_date. Device categories were extracted from product_description field keyword matching. Note that the product_code field is blank in this dataset for all records; device categorization is based on text analysis of product descriptions.

Cross-referencing was done with FDA's Medical Device Recalls and Early Alerts page and the broader FDA device recall database (58,374 events) for context.

What Is a Class I Recall?

Under 21 CFR 7.3, FDA classifies recalls into three tiers based on the health hazard presented:

Class I recalls are comparatively rare — just 9.0% of all classified enforcement events — but they carry the highest regulatory and commercial stakes. FDA dedicates disproportionate resources to tracking Class I recalls because of their severity. As Reid noted at MedCon, "the ones that really are resource labor intensive to track and monitor are those Class Is."

Importantly, FDA classification is not taken lightly. "When CDRH classifies a Class I recall, they do their due diligence," Reid emphasized. "It's not an insignificant thing when they classify your recalls."

Year-Over-Year Trend: The Post-2020 Escalation

The annual volume of Class I recalls has fluctuated significantly over the past two decades, with several notable spikes:

Three structural patterns emerge:

1. Single-firm events can dominate annual totals. In 2014, Customed, Inc. alone accounted for 74.4% of all Class I recalls (412 of 554). In 2019, Medtronic Vascular drove 51.9% (191 of 368). In 2023, Teleflex drove 21.1% (123 of 584). These are not systemic industry-wide shifts — they are firm-specific quality failures that inflate the annual number.

2. The baseline is rising. Even after excluding the largest single-firm contributor each year, the "adjusted" Class I count has trended upward: 142 (2014), 177 (2019), 461 (2023), 251 (2024), 329 (2025). This is consistent with FDA's stated concern about the 232% increase from 2020 to 2025.

3. FDA's Early Alert / Communications Pilot. In November 2024 CDRH launched a pilot to accelerate public disclosure of high-risk device recalls, initially covering cardiovascular, gastrorenal, general hospital, obstetrics and gynecology, and urology devices. The pilot cut the gap between recall initiation and public alert from roughly 2–3 months to about 1–3 weeks, and on 29 September 2025 FDA expanded Early Alerts to all device recalls likely to be classified as the most serious type.

Top Recalling Firms: Concentration in Cardiovascular and Hospital Devices

Among all 3,510 Class I recalls, the top 15 firms account for 1,589 events (45.3%):

Focusing on recent years (2019–2026), Medtronic's combined divisions account for 330 events — nearly 15% of all Class I recalls in this period:

The dominance of cardiovascular firms (Medtronic, Boston Scientific, Arrow) reflects the inherently high-risk nature of cardiovascular and implantable devices — any defect in a pacemaker, defibrillator, or vascular catheter has the potential for life-threatening consequences, warranting Class I classification.

Device Categories Most Affected

Based on keyword analysis of product descriptions across all 3,510 Class I recalls:

Several observations:

• Catheter and vascular device recalls are the largest single category, driven by the Medtronic Vascular recalls (203 events) and Arrow International (42 events). Common failure modes include guidewire entrapment, catheter tip occlusion, and introducer sheath separation.

• Ventilation-related recalls (ventilators + breathing circuits + endotracheal tubes = 782 events combined) represent the broadest device cluster. The Philips Respironics recall — one of the most significant device safety events in recent history — accounts for 80 events in this category, but the problem extends well beyond a single manufacturer.

• Surgical kits and trays account for 444 events, heavily influenced by the Customed/Medline recalls involving contaminated or incorrectly assembled kits. While individual events may seem routine, the volume is significant because these products reach virtually every hospital.

Root-Cause Patterns from Recall Reasons

Analysis of the reason_for_recall field reveals several recurring root-cause themes:

Manufacturing and Material Defects

The most common trigger. Examples include:

• Catheter tip occlusion — material obstruction found in the catheter lumen (multiple firms)
• Breathing circuit disconnection — glued connections becoming loose during ventilation
• Syringe plunger disconnection — plunger separating from the syringe barrel during use

Design-Related Failures

• Connector disconnection — endotracheal tube connectors separating from the tube
• Introducer sheath separation — bond site failure at the proximal end
• Battery depletion — premature battery run-time in critical devices (intra-aortic balloon pumps, pacemakers)

Software and Electronics

• Energy delivery failure — reduced or no-energy output during high-voltage therapy in defibrillators
• Software safety mode — unintended initiation of safety mode in insulin pumps
• Alarm failure — ventilator alarm systems not activating when conditions warrant

Sterility and Contamination

• Contaminated components — surgical kits manufactured with contaminated components or non-sterile items included in sterile kits
• Material debris — loose material found in device lumens or packaging

Geographic Distribution of Recalling Firms

The concentration in Minnesota and Massachusetts reflects the cardiac device industry's hub in the Minneapolis–St. Paul and Boston corridors. Puerto Rico's high count is driven by Medtronic's manufacturing operations there, which appear as the recalling firm location for the Medtronic Vascular division's events.

Regulatory Context and Industry Response

FDA has acknowledged the Class I recall trend publicly and is taking several steps:

1. Early Alert pilot and expansion. CDRH's November 2024 pilot accelerated public alerts for potentially high-risk recalls — initially in cardiovascular, gastrorenal, general hospital, obstetrics/gynecology, and urology devices — compressing disclosure from roughly 2–3 months to about 1–3 weeks. FDA deemed the pilot successful and, on 29 September 2025, expanded Early Alerts to all recalls likely to be classified as the most serious type.

2. Recall termination challenges. FDA's Reid acknowledged the agency is not meeting its goals for terminating recalls, citing insufficient staffing, IT systems, and additional authorities as limiting factors. A recent Government Accountability Office (GAO) report recommended both FDA and HHS address limitations in recall oversight.

3. QMSR transition (February 2026). The new Quality Management System Regulation (QMSR), which replaces the Quality System Regulation (QSR, 21 CFR Part 820) and incorporates ISO 13485:2016 by reference, became effective on February 2, 2026. The transition may affect how manufacturers approach design controls, CAPA, and production processes — all of which are root causes of Class I recalls.

4. Increased inspection activity. FDA device warning letters citing QSR violations reached 19 in the first eight months of 2025, compared to 12 in the same period of 2024. This enforcement uptick is occurring alongside the Class I recall increase.

Implications for Manufacturers

The data suggests several actionable insights for quality and regulatory professionals:

• Cardiovascular and respiratory device manufacturers face the highest Class I risk. The combination of high-risk patient populations, complex device designs, and stringent FDA classification criteria means these product categories are disproportionately represented.

• Single-firm events can dominate. Companies like Customed (2014) and Medtronic Vascular (2019) show that a single quality failure can inflate the industry-wide Class I count. Internal vigilance and robust CAPA systems remain the primary defence.

• Catheter and connector design demands special attention. Disconnection, occlusion, and separation events are recurring themes across multiple firms and product types, suggesting systemic design challenges in these device categories.

• Ventilation device safety is under heightened scrutiny. The Philips recall and the broader ventilation-related recall cluster (782 events) signal that FDA and the industry are grappling with safety in this device class.

• Recall response speed matters more than ever. FDA's Communications Pilot means that Class I recalls will become public faster, compressing the timeline for manufacturer response, notification, and remediation.

Key Takeaways

• 3,510 Class I recalls from 2006 to June 2026, representing 9.0% of all classified enforcement events
• FDA reports a 232% increase in Class I recalls from 2020 to 2025 (Reid, MedCon 2026); this article's independent event-level count rose 137% over the same period (159 → 377)
• Medtronic leads with 346 combined events across Vascular and CRHF divisions
• Catheters and ventilation devices are the most frequently recalled device categories
• Manufacturing defects and connector failures are the dominant root causes
• Minnesota and Massachusetts are the geographic centres of Class I recall activity
• FDA's Communications Pilot is accelerating public disclosure of Class I events

Data Source

Analysis sample: FDA enforcement report database (public dataset, extracted June 2026), 39,096 classified recall events. Class I subset: 3,510 events. Year assignment based on recall initiation date. Device categorization derived from keyword analysis of product description field. Cross-referenced with FDA's Medical Device Recalls and Early Alerts page and FDA officials' statements at the 2026 MedCon conference.